in the dorsolateral (79%) and ventromedial (57%) putamen. The dorsolateral region was better preserved in dementia-predominant cases than in cases with parkinsonism. Dorsolateral putaminal tyrosine hydroxylase immunoreactivity correlated with neuronal loss in the ventrolateral substantia nigra. Genetic analyses showed no significant association of PD risk variants with putaminal tyrosine hydroxylase immunoreactivity.
Conclusions:
The results confirm regional differences in putaminal dopaminergic degeneration and vulnerability of nigrostriatal pathway in Lewy body disorders with parkinsonism. The lack of association with PD genetic risk variants suggests that they may not be associated with quantitative endophenotypes of nigrostriatal degeneration, but more likely related to the risk of disease per se. , and dementia with Lewy bodies (DLB). 1 A high proportion of Alzheimer's disease (AD) patients also have LBs, but their contribution to the clinical syndrome is unclear. 2 The neuropathologic features of LB disorders include not only LBs but also Lewy neurites, axonal spheroids, and sparse glial inclusions, 3 all of which contain aggregates of a-synuclein. 4, 5 Striatal dopamine depletion is a striking neurochemical feature of PD that correlates with motoric deficits. 6 Striatal dopamine loss is secondary to neurodegeneration of the nigrostriatal system, in particular the loss of neurons in the ventrolateral cell groups of the substantia nigra, 4 with variable involvement of the medial region of the substantia nigra. 7 A number of methods have been used to detect dopaminergic degeneration, including immunohistochemistry for tyrosine hydroxylase (TH-ir), vesicular monoamine transporter, and dopamine transporter. 8, 9 Reduction in TH-ir is sensitive and can be detected in preclinical PD, 10 sometimes referred to as incidental LBD. 11, 12 Kordower and colleagues 8 recently reported regional differences in nigrostriatal dopaminergic integrity in the putamen, with loss of TH-ir in the dorsolateral putamen within 4 years of symptomatic onset of PD; however, they limited their study to PD and did not include subjects with PDD or DLB. In the present study, we performed a similar regional analysis of nigrostriatal dopaminergic integrity using TH immunohistochemistry in pathologically confirmed LBD patients with a range of clinical phenotypes and correlate these findings with genetic risk variants associated with PD. We also correlated putaminal TH-ir with estimates of neuronal loss in the substantia nigra. The first aim of our study was to clarify regional differences of putaminal dopaminergic degeneration with respect to clinical and pathologic features in LBD. The second aim was to explore possible genetic associations between dopaminergic neurodegeneration and PD genetic risk variants identified from genome-wide association studies (GWAS). We tested the hypothesis that PD genetic variants, in addition to their previously demonstrated ability to alter risk of PD, 13, 14 would also correlate with pathologic endophenotypes that are highly correlated with parkinsonism. Our rationalization for including LBD cases not only with Parkinsonism but also those with dementia as a contributing or primary clinical syndrome was the notion that PD genetic risk loci would track with nigrostriatal degeneration regardless of clinical features given that the risk loci were identified in patients with parkinsonism. To this end, we explored relationships between risk loci and quantitative measures of nigrostriatal dopaminergic degeneration, which is thought to be basis for the extrapyramidal signs in PD.
Materials and Methods

Study Samples
All cases had LB pathology and were from the brain bank for neurodegenerative disorders at Mayo Clinic in Jacksonville, Florida. Cases with mutations in a-synuclein gene (SNCA) or leucine-rich repeat kinase-2 gene (LRRK2) and the cases with infarcts or hemorrhages in midbrain or putamen were excluded. For comparison, we also studied 17 age-, sex-, brain weight-, and postmortem interval-matched neuropathologic controls with minimal or no Alzheimer and no Lewy-related pathology using the same methods. Brains were acquired from autopsies after consent of the legal next of kin or an individual with power of attorney. The Mayo Clinic Institutional Review Board has determined that studies with postmortem tissue are exempt from human subject regulations.
Clinical Classification of Cases
We classified all LBD cases into 1 of the following 3 clinical subgroups according to their predominant antemortem syndrome ascertained from medical record review: parkinsonism predominant, parkinsonism1dementia, or dementia predominant. Parkinsonism-predominant cases included PD as well as individuals misdiagnosed with a parkinsonian disorder without significant cognitive impairment, including multiple system atrophy and progressive supranuclear palsy. None of the cases had neuropathologic features of multiple system atrophy or progressive supranuclear palsy. Individuals with clinical diagnoses associated with both cognitive and motor impairment, including corticobasal syndrome, PDD, and DLB, were included in the parkinsonism1dementia group. Individuals with clinical diagnoses of Alzheimer type dementia or frontotemporal dementia were included in the dementia-predominant group. Cases with incidental LBD presenting only with rapid eye movement sleep behavior disorder or other nonmotor features without dementia or parkinsonism were not included.
Neuropathologic Assessment
The diagnostic evaluation included quantitative assessment of neurofibrillary tangles and senile plaques with thioflavin S fluorescent microscopy, with assignment of Braak neurofibrillary tangle stage and Thal amyloid phase according to previously reported methods. [15] [16] [17] Sections were cut from paraffin embedded tissue at 5-mm thickness and processed for a-synuclein immunohistochemistry (NACP, rabbit polyclonal, 1:3000; Mayo Clinic antibody) with a method that gives comparable results to other a-synuclein immunohistochemistry methods. 18 LB subtypes (brainstem, transitional, and diffuse [ Table 1 ]) were assigned using published guidelines. 1 The putamen was evaluated at the level of the anterior commissure from a section made from the hemibrain in a standardized dissection plane defined by 3 points in the fundibulum, uncus, and posterior margin of the anterior commissure in the 3rd ventricle. The level chosen for evaluation of the putamen was similar to that used in the previous report on regional differences in dopaminergic degeneration in PD. 8 Digital images of the putamen were parcellated into dorsolateral and ventromedial areas, 19 and dopaminergic degeneration was assessed quantitatively.
Quantification of Striatal Dopaminergic Integrity
The basal ganglia section was processed for immunohistochemistry using a commercially available antibody to TH (rabbit polyclonal, 1:600; Affinity Bioreagents, Golden, Colorado). The immunostained sections were captured by ScanScope XT (Aperio Technologies, Vista, California), and images were annotated with ImageScope (version 12.1). Regions of interest were manually edited to exclude artifacts, large blood vessels and their perivascular spaces, and large fiber bundles (Fig. 1C) . The putamen was subdivided into dorsolateral (Fig. 1C[i] ) and ventromedial regions similar to the regions studied by Kordower and colleagues. 8 To standardize the 2 regions of interest, we developed operational rules. The ventromedial region consisted of 2 regions as follows: a medial portion was defined by a curvilinear line that started at the dorsal border of the putamen set at 1/7 of the length of the dorsal border and drawn parallel to the striatopallidal margin (Fig. 1C[ii] ) and a ventral wedge defined by a line between the lower 1/10 of the medial putamen and the outer margin of dorsolateral putamen ( Fig. 1C[iii] ). Quantification of TH-ir used an algorithm that detected positive pixels (red) based on optical density. It was expressed as a percentage, calculated as the positive pixels divided by the sum of inverse pixels (blue) and background pixels (yellow; Fig. 1D ).
Semiquantitative Assessment of Substantia Nigra Pigmented Neuronal Loss
The midbrain was a transverse section at the level of the third nerve similar to that recommended for diagnostic evaluation of PD. 4 Semiquantitative assessment of substantia nigra cell groups was ascertained on hematoxylin and eosin stained sections at 100 3 magnification. We limited assessment to pigmented neurons of substantia nigra pars compacta and divided it into 2 sectors-medial and ventrolateral (Fig. 1E )-similar to regions used in previous clinicopathologic studies. 7, 20 We used a human atlas of substantia nigra cell groups to identify ventrolateral and medial regions of the substantia nigra. 21 The density of nonpigmented neurons was not taken into consideration for the semiquantitative scores based on a 4-point scale: 0, none; 1, mild; 2, moderate; and 3, severe. 4 
Genetic Analyses
Genomic DNA was extracted from frozen cerebellar tissue by standard procedures. Genotyping was performed with a combination of Agena Bioscience Sequenom MassARRAY system (Agena Bioscience, Values are given as n (%) or median (interquartile range). Postmortem delay, h 5 hours; LBD, Lewy body disease; D 5 dementia predominant; P1D, parkinsonism1dementia; P, parkinsonism predominant; TH-ir, tyrosine hydroxylase immunoreactivity; AD, Alzheimer's disease; NFT, neurofibrillary tangle. LBD types: BLBD, brainstem; TLBD, transitional; DLBD, diffuse.
San Diego, California) and TaqMan SNP genotyping assays (Applied Bio-systems, Carlsbad, California) to determine genotype calls for 29 PD risk variants (Supplemental Table 1 ). PD risk variants were 28 single nucleotide polymorphisms previously identified as independent genetic risk factors for PD in a genomewide association meta-analysis. 13 An additional variant (TCEANC2 rs10788972) that was identified as a risk for PD in a genome-wide association analysis and pathologically confirmed was also assessed. All call rates were >95%, and there was no evidence of departure from the Hardy-Weinberg equilibrium for any of the variants (all P > .01), except for HLA-DQB rs13201101 (P < .001), which was driven by an excess of rare homozygotes.
Statistical Analyses of Genotyped Single Nucleotide Polymorphisms With Pathologic Traits
Considering race and ethnicity as a potential confounding factors and the lack of variation in race and ethnicity in LBD cases, only non-Hispanic whites were included in the genetic association analyses. The examination of genetic associations with pathological endophenotypes was limited to the following 2 pathologic traits with continuous variables: dorsolateral and ventromedial putaminal TH-ir. The association of each single nucleotide polymorphism and dorsolateral and ventromedial putamen TH-ir was examined by linear regression models adjusted for age at death, sex, Braak neurofibrillary tangle stage, and Thal amyloid phase. These associations were also examined in a clinical subgroups of any parkinsonism (parkinsonism predominant and parkinsonism1dementia) as well as parkinsonism1dementia and parkinsonism predominant, alone. Dorsolateral putaminal TH-ir was considered on a logarithm scale and ventromedial putaminal TH-ir was considered on the square root scale in linear regression analysis owing to their skewed distributions. Using a Bonferroni correction to adjust for multiple testing for each different outcome, P values of .0017 or lower were considered statistically significant. We also tested polygenic association with the aforementioned pathologic traits using a genetic risk score, which was calculated as described by Nalls and colleagues. 13 Statistical analyses for genetic associations were performed using SAS (version 9.2; SAS Institute, Inc., Cary, North Carolina).
Other Statistical Analyses
To compare demographic and neuropathologic variables between parkinsonism-predominant, parkinsonism1 dementia, and dementia-predominant subgroups, a chisquare test was used for categorical variables, and a Kruskal-Wallis rank sum test was used for ordered categorical or continuous variables. Given a significant . For image analysis, artifacts, large fiber tracts, and blood vessels were manually edited (dashed circle) on each section. (D) A color deconvolution-based algorithm was used to measure TH-ir. A positive pixel count algorithm was customized to quantify brown immunoreactive pixels (red markup), subtracting inverse (blue) and background pixels (yellow). Transverse section of the unilateral midbrain is shown (E). Warped rectangles show the lateral and medial substantia nigra. Semiquantitative assessment of neuronal loss in the substantia nigra is provided. Abundant pigmented neurons are seen in a neurologically normal control (score 0; F), compared with variable neuronal loss in Lewy body diseasemild (score 1; G), moderate (score 2; H), and severe (score 3; I). Scale bars: A to C 5 2 mm; D 5 100 mm; E 5 1 cm; F to I 5 250 mm.
overall difference between the 3 subgroups, pairwise comparisons were made using a chi-square test (categorical variables) or a Mann-Whitney test (ordered categorical or continuous variables). Spearman's test of correlation was used to examine the associations between striatal endophenotypes (putaminal TH-ir) and midbrain neuronal loss, overall and separately according to the 3 clinical subgroups. Paired Wilcoxon signed rank tests were used to compare dorsolateral and ventromedial putaminal TH-ir. We used a Bonferroni correction to adjust for multiple testing separately for each group of similar statistical tests. P values .0038 (comparisons of demographic and pathologic variables between the 3 subgroups) and .0031 (correlations between putaminal TH-ir and midbrain neuronal loss) were considered significant. For comparisons of demographic and pathologic variables between the dementia-predominant, parkinsonism1dementia, and parkinsonism-predominant subgroups, if a significant (P .0028) overall difference was identified, pairwise tests were then performed using a second Bonferroni correction, where P .0167 was considered significant. All statistics other than the genetic analyses were performed with SigmaPlot (version 12.0; Systat Software Inc., Chicago, Illinois).
Results
Demographic and Clinical Characteristics of the Autopsy Cohort
A total of 492 cases of pathologically confirmed LBD were included in the study. Most had common antemortem clinical syndromes (PD, n 5 29; PDD, n 5 72; DLB, n 5 111; and AD, n 5 201), whereas 65 cases (13%) had uncommon clinical presentations, including frontotemporal dementia (n 5 9), corticobasal syndrome (n 5 7), multiple system atrophy (n 5 19), progressive supranuclear palsy (n 5 30), and others (n 5 14). All cases were categorized into 1 of the following 3 clinical subgroups: parkinsonism-predominant (n 5 80), parkinsonism1dementia (n 5 195), and dementia predominant (n 5 217). The clinical and pathologic characteristics of the 3 subgroups are summarized in Table 1 . The dementia-predominant subgroup had female predominance (52%) as well as higher median age at death (81 years old) when compared with the other subgroups. In contrast, the parkinsonism-predominant and parkinsonism1dementia subgroups were younger (median ages of 78 and 76 years old, respectively) and had a male predominance (70% and 66%, respectively).
Pathologic Characteristics of the Clinical Subgroups
Brain weights differed significantly between the 3 clinical subgroups (P < .001) and were least in the dementia-predominant subgroup (median 1080 g). Postmortem intervals were not significantly different across the subgroups (P 5 .064). In all clinical subgroups, the most frequent LB type was diffuse cortical type; the distribution of LB types differed between the clinical subgroups (P < .001). Diffuse LB pathology was most frequent in the parkinsonism1dementia subgroup (64%), and lowest in the parkinsonismpredominant subgroup (39%; Table 1 ).
Of the 492 LBD cases included in this study, 212 cases (43%) had intermediate-to-high AD neuropathologic change. 22 As might be expected, the frequency of comorbid AD pathology was greatest in the dementiapredominant subgroup (75%) and lower in parkinsonism1dementia (22%) and parkinsonism-predominant (9%) subgroups. Alzheimer neuropathologic change summarized by Braak stage and Thal phase showed gradation in decreasing order from dementia predominant to parkinsonism1dementia to parkinsonism predominant, with significant differences between each subgroup. Following this order, the frequency of putaminal amyloid (Thal phases 3 or greater) varied; 90%, 70%, and 45%, respectively (data not shown). The parkinsonism-predominant group had the lowest Braak stage (median III, interquartile range II-III) and Thal phase (median 1, interquartile range 0-3).
Neuronal loss in the ventrolateral substantia nigra was more marked than in the medial substantia nigra. Both the ventrolateral and the medial substantia nigra had significantly greater neuronal loss in the parkinsonismpredominant and parkinsonism1dementia subgroups than in the dementia-predominant subgroup.
Striatal Dopaminergic Integrity
To put the LBD cases in context, neurologically normal controls processed identically showed robust THir in both the dorsolateral and ventromedial putamen (dorsolateral: median 21, interquartile range 14-31; ventromedial: 23, interquartile range 17-25), and no regional difference between the 2 regions (P 5 .84). In contrast, there was significant decrease in TH-ir in the putamen in brains with LBD (dorsolateral: median 4, interquartile range 2-8, range 0.3-42, ventromedial: median 10, interquartile range 6-14, range 0.3-29) with a notable degree of variation in these measures. TH-ir in the ventromedial putamen was relatively preserved compared to the dorsolateral putamen (representative case is shown in Fig. 1B) , with a reduction in the dorsolateral of 79% compared to 57% for the ventromedial putamen. Among the clinical subgroups, TH-ir in the dorsolateral putamen was better preserved in the dementia-predominant subgroup (median 6, interquartile range 3-12) when compared with the parkinsonism1dementia (median 3, interquartile range 2-6) and parkinsonism-predominant subgroups (median 3, interquartile range 2-5; Table 1 ). There
was no difference in TH-ir in the ventromedial putamen across clinical subgroups (P 5 0.86; Table 1 ).
Correlation Between Putaminal TH-ir With Midbrain Neuronal Loss
When considered as a whole, TH-ir in the dorsolateral putamen had an inverse correlation with neuronal loss in both ventrolateral substantia nigra (r 5 20.46, P 5 2.0 3 10
27
) and medial substantia nigra (r 5 20.32, P 5 5.7 3 10
212
; Table 2 ). This finding also held true when considering the 3 clinical subgroups. In contrast, TH-ir in the ventromedial putamen correlated with neuronal loss in the ventrolateral substantia nigra only for overall group (r 5 20.15, P 5 .0007), but did not correlate with it for any of the 3 clinical subgroups. TH-ir in the ventromedial putamen correlated with neuronal loss in the medial substantia nigra overall (r 5 20.21, P 5 5.8 3 10
26
) and in the parkinsonism1dementia (r 5 20.22, P 5 .003) and parkinsonism-predominant subgroups (r 5 20.31, P 5 .003).
Associations of PD Genetic Risk Variants With TH-ir
Genetic analyses were performed on 473 of the 492 cases (96%). A summary of allele and genotype counts and frequencies are shown in Supplemental Table 1 ; observed allele frequencies were very similar to those previously reported. 13, 14 Regarding the association between PD genetic risk variants and 2 continuous variable pathologic endophenotypes (dorsolateral and ventromedial putaminal TH-ir), no significant associations were detected after Bonferroni correction in the overall LBD series (Table 3 ). In subanalyses for groups showing any parkinsonism (parkinsonism predominant or parkinsonism1dementia) or parkinsonism predominant, 1 variant of SNCA (rs3910105) showed nominally significant association with the ventromedial putamen TH-ir (P 5 .009) in the parkinsonismpredominant subgroup; however, none of the variants showed significant association with any of the pathologic traits after correction (Table 4, Supplemental Table 2 ). The median PD genetic risk score was 3.1 (range 2.0-4.9), and there was no significant association between it and any of the pathologic traits (all P .13). The lack of association with PD genetic risk score was similar when examining any parkinsonism (parkinsonism1dementia and parkinsonism predominant), parkinsonism1dementia, and parkinsonism-predominant subgroups, separately (data not shown).
Discussion
In the present study, the integrity of the nigrostriatal dopaminergic innervation was measured by image analysis of putaminal TH-ir in a large number of brains with pathologically confirmed LB pathology and a range of clinical presentations. We found significant regional differences in vulnerability of the putamen to dopaminergic neurodegeneration, with dorsolateral more affected than ventromedial, as noted by others. 8 This fits with evidence that the dorsolateral putamen has projections from the most vulnerable neuronal cell group in the substantia nigra, the ventrolateral cell group. Although degeneration was less severe in the ventromedial putamen, it was significantly different from neurologically normal controls. Moreover, there was inverse correlation between ventromedial putamen dopaminergic innervation and neuronal loss in the medial region of substantia nigra, whereas the correlation was weak or absent for the ventrolateral substantia nigra neuronal loss. These observations fit with evidence that this part of the putamen receives dopaminergic innervation from less vulnerable neurons in the medial region of substantia nigra that are affected only in later stages of PD. 8 Dopaminergic nerve terminal loss in the dorsolateral putamen was greater in the parkinsonian subgroups (parkinsonism predominant and parkinsonism1dementia) than in the dementia-predominant subgroup. In contrast, no differences were detected across clinical subgroups for the ventromedial putamen TH-ir. These findings might suggest that estimates of substantia nigra neuronal loss and dorsolateral putaminal dopaminergic integrity measured objectively with digital microscopy would be excellent endophenotypes for parkinsonism. 
Ventrolateral region
P values are from Spearman's test of correlation. TH, tyrosine hydroxylase. P .0031 are considered statistically significant after Bonferroni correction.
The failure to find association with PD genetic risk variants identified from GWAS suggests that genetic variants may be related to risk of PD, but not pathologic endophenotypes (ie, nigrostriatal degeneration). Among clinical PD cohorts, a number of previous studies have linked specific genetic variants with clinical phenotypes, [23] [24] [25] [26] [27] [28] and it has been reported that using the polygenic risk score can correlate with motor progression in PD and potentially age at onset. [29] [30] [31] In addition, relatively rare glucosylceramidase-B (GBA) mutations 28 have been linked with progression of both cognition and motor deficits in PD, whereas apolipoprotein E(APOE) has been linked to cognition 28 and common SNCA variants with motor deficits. 23 This discordance could be in part a result of clinical heterogeneity or the nature of assessing end-stage pathology. It is also worth noting that GBA and alternate SNCA alleles have been implicated in cognitive measures versus susceptibility to PD, 29 thus again demonstrating the need for large unbiased genome-wide approaches using nigrostriatal degeneration as the endophenotype.
Interestingly, our findings are quite different from the effects of APOE genotype on both risk for AD 32 and on the severity of Alzheimer-related pathologic endophenotypes. 33 Bennett and colleagues 33 found a robust association between APOE and pathologic traits (P 5 9 3 10 224 ), which was many fold greater than the association with risk of clinical diagnosis of AD in the same cohort (P 5 3 3 10
27
). Apolipoprotein E may contribute to AD risk and pathogenesis through multiple pathways. 34 It remains unclear how many of the PD susceptibility gene variants contribute to the risk of PD. The results of the present study seem to suggest that they do not associate with the severity of nigrostriatal dopaminergic degeneration. PD is a multifactorial disease process affected by genetic, epigenetic, and environmental factors. [35] [36] [37] In addition, we considered several factors that might have weakened the correlation. First, the selected common variants were identified from GWAS and based on a case-control approach. This method selects for variants enriched in the disease group compared to healthy controls and might fail to detect genetic variants that contribute to disease severity or heterogeneity of PD, such as nigrostriatal neurodegeneration assessed in the present study. This study has shown the need for unbiased genome-wide approaches (eg, GWAS or whole-genome sequencing) to resolve genetic variation that can drive this pathology. Second were the possibly weak effects of individual genetic variants; to overcome this, we created a weighted genetic risk score similar to that used by Nalls and colleagues 13 based on the effect size of the genetic variant and the frequency of the variant. Unfortunately, the genetic risk score also failed to show association with the quantitative endophenotype, dorsolateral putaminal TH-ir, which is highly correlated with parkinsonism. 8 Third, interactions of other genetic and nongenetic factors may have masked the genetic association with pathologic traits. It has been emphasized that the interplay of these factors may play a key role in function or dysfunction of susceptibility genes. 35, 36, 38 Soldner and colleagues recently identified a specific risk variant (rs356168) of the SNCA gene that has cisregulatory effects on a noncoding distal enhancer element that could contribute to PD pathogenesis. 38 Attempts to disentangle the contribution of these modifier factors on the effects of genetic variants identified from case-control studies may be needed. These studies may also include other candidate genetic determinants of neurodegenerative pathologies (eg, hits from AD GWAS) as a large number of patients with AD have LB pathology at end stage. It is likely a large unbiased strategy using GWAS or whole-genome sequencing approaches will help dissect the genetic architecture of nigrostriatal degeneration. Finally, the power to detect associations between genetic variants and TH-ir was limited in the relatively small parkinsonism predominant subgroup (n 5 80), and therefore the possibility of a type II error is important to consider.
Despite its limitations, we believe that there are the following strengths of our study: (1) it is based on a large autopsy-proven cohort of LBD cases; (2) the endophenotype for nigrostriatal integrity, TH-ir in the putamen, was objectively measured with digital Regression coefficients; 95% CIs; and P values result from linear regression models adjusted for age at death, sex, Braak stage, and Thal phase. A regression coefficient above 0 indicates that dorsolateral or ventromedial putamen TH-ir was higher for patients with a copy of the minor allele of the given variant. (After applying a Bonferroni correction for multiple testing, P values of .0017 or lower are considered as statistically significant.) CI, confidence interval; MAF, minor allele frequency; TH-ir, tyrosine hydroxylase immunoreactivity. pathology and an unbiased color deconvolution algorithm; and (3) all of the currently known PD genetic variants identified by clinical and autopsy GWAS were included in the statistical analysis of endophenotypes. In summary, our anatomical findings regarding the regional anatomy of putamen dopaminergic innervation confirm and extend previous observations on selective vulnerability of striatonigral and mesolimbic dopaminergic systems in LBD. Failure to find genetic correlates with quantitative endophenotypes that tract closely with extrapyramidal signs in PD may suggest that PD genetic risk factors influence the risk of PD, but not the severity of pathologic processes linked to parkinsonism, which is unlike findings in AD. Further studies are needed to understand the pathogenetic mechanisms of PD genetic risk loci, including expanding studies of pathologic endophenotypes such as those used in this study to larger multicenter cohorts of pathologically confirmed PD. 
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